

Production of Preclinical and clinical samples of TROP2-ADC for IND filing and approval, or technology transfer

LegoChem Biosciences, Inc.



ONCOLOGY	Non-Clinical
Product Type	Antibody Drug Conjugate (ADC)
Indication	1st indication : Breast cancer including TNBC, non-small cell lung cancer, Colorectal cancer, Gastric cancer, Pancreatic cancer 2nd indication : TROP2 expressing solid tumor (Ovarian cancer, etc.):
Target	TROP2 (tumor associated calcium signal transducer 2)
MoA(Mechanism of Action)	Binding to cell surface antigen → Endocytosis → Lysosomal degradation → active payload release → Cell death
Competitiveness	Antibody : Preferable binding of ADC to tumor selective cleaved-TROP2 antigen Linker : Tumor selective enzyme cleavable linker Payload : mono-methyl auristatin E (MMAE), tubulin inhibitor
Development Stage	Non-Clinical
Route of Administration	Parenteral-Intravenous